AI PLATFORM TECHNOLOGIES We strive to develop novel drugs with an unprecedented level of efficacy and precision. Using AI, we simulate the human immune system and generate predictive models to identify and develop personalized and other next-generation immunotherapies for patients.

ONCOLOGY

PIONEER is our proprietary AI platform for the rapid discovery of patient-specific neoantigens used for our personalized cancer immunotherapies. We want to challenge and improve the standardized therapies of today, where one size fits all, risking unspecific immune activation. With our AI technologies, we seek out and target cancer cells, creating truly personalized therapies, where one size fits one and only one.

Related Resources

<p>Evaxion Announces NIH Grant for Research Collaboration With UMass Chan Medical School</p>

Sep 6, 2022

News

Evaxion Announces NIH Grant for Research Collaboration With UMass Chan Medical School

<p>Evaxion Biotech Announces Gonorrhea as Second Bacterial Product Target</p>

Jun 30, 2022

News

Evaxion Biotech Announces Gonorrhea as Second Bacterial Product Target

<p>Evaxion Biotech Expands Its EVX-03 DNA Vaccine Program Into Non-Small Cell Lung Cancer</p>

Jun 23, 2022

News

Evaxion Biotech Expands Its EVX-03 DNA Vaccine Program Into Non-Small Cell Lung Cancer

<p>Evaxion Biotech Secures Equity Financing of up to $40 Million from Lincoln Park Capital</p>

Jun 7, 2022

News

Evaxion Biotech Secures Equity Financing of up to $40 Million from Lincoln Park Capital